Home/Filings/4/0001437749-24-035887
4//SEC Filing

Lorrain Daniel S. 4

Accession 0001437749-24-035887

CIK 0001855175other

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 5:07 PM ET

Size

7.4 KB

Accession

0001437749-24-035887

Insider Transaction Report

Form 4
Period: 2024-11-18
Lorrain Daniel S.
Chief Scientific Officer
Transactions
  • Sale

    Class A Common Stock

    2024-11-18$16.37/sh6,091$99,733169,671 total
  • Sale

    Class A Common Stock

    2024-11-18$17.05/sh99$1,688169,572 total
Holdings
  • Class A Common Stock

    (indirect: By Spouse)
    3,898
Footnotes (3)
  • [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.03 to $17.02, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  • [F3]Includes 325 shares purchased through Issuer's Employee Stock Purchase Plan.

Issuer

Contineum Therapeutics, Inc.

CIK 0001855175

Entity typeother

Related Parties

1
  • filerCIK 0001861550

Filing Metadata

Form type
4
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 5:07 PM ET
Size
7.4 KB